Références

Triez par catégorie, par ordre alphabétique ou recherchez une référence par mot clé.

Ré‚ference
Catégorie
Lien
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011 May 12;117(19):5019-32.Diagnostic - Classifications
Kaplan HS. Hodgkin´s disease. Cambridge: Mass: Harvard University Press, 1980Diagnostic - Classifications
Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest 2012;122:3439-47.Diagnostic - Classifications
Küppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2012,328-34. doi: 10. 1182/asheducation-2012. 1.328. Review. Diagnostic - Classifications
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin´s disease: Cotswolds meeting. J Clin Onol 1989;7:1630-1636. Diagnostic - Classifications
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds): WHO Classsification of Tumours of Haematopoietic and Lymphoid Tissues.Lyon: IARC; 2008Diagnostic - Classifications
Teillet F, Weisgerber C, Desprez-Curely JP, Bousquet R, Boiron M, Bernard J. L´extension du processus hodgkinien. Étude clinique. Bull Cancer 1971; 58: 45-56Diagnostic - Classifications
Casasnovas RO, Mounier N, Brice P, et al. Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin’s Lymphoma: A Study From the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol, 2007, 25:1732-1740.Facteurs de Risque - Index pronostiques
Eghbali H, Raemaekers J, Carde P; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol 2005;66(suppl):135-40.Facteurs de Risque - Index pronostiques
Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v168-71. Facteurs de Risque - Index pronostiques
Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009 Sep 20;27(27):4555-62.Facteurs de Risque - Index pronostiques
Gallagher CJ, Gregory WM, Jones EA, et al. Follicular lymphoma : prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80.Facteurs de Risque - Index pronostiques
Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004 Apr 1;103(7):2474-9. Facteurs de Risque - Index pronostiques
Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013;31(2):256-62.Facteurs de Risque - Index pronostiques
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin´s disease. International Prognostic Factors Project on Advanced Hodgkin´s Disease. N Engl J Med 1998; 339:1506-1514 Facteurs de Risque - Index pronostiques
Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic indes in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol 2014 May 1;32(13):1338-46. Facteurs de Risque - Index pronostiques
Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Annal Oncol 2013 Sep ;24(9) :2430-4.Facteurs de Risque - Index pronostiques
Maurer MJ, Ghesquières H, Jais JP, et al. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol 2014 Apr 1;32(10):1066-73.Facteurs de Risque - Index pronostiques
Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma : altered utility in the modern era. J Clin Oncol 2012;30(27):3383-8.Facteurs de Risque - Index pronostiques
Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 2012;97(2):262-69.Facteurs de Risque - Index pronostiques
Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Facteurs de Risque - Index pronostiques
Sánchez-Espiridión B, Montalbán C, López A, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116:e12-e17.Facteurs de Risque - Index pronostiques
Sieber M, Engert A, Diehl V. Treatment of Hodgkin´s disease: results and current concepts of the German Hodgkin´s Lymphoma Study Group. Ann Oncol 2000; 11 suppl1: 81-85 Facteurs de Risque - Index pronostiques
Shen LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007 March 1;109:1857-1861.Facteurs de Risque - Index pronostiques
Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004 ;104 :1258-65.Facteurs de Risque - Index pronostiques
Somers R, Henry-Amar M, Meerwaldt JK, Carde P, eds. Treatment strategy in Hodgkin’s disease. Colloque INSERM N° 196. London : INSERM/John Libbey Eurotext, 1990 :169-422.Facteurs de Risque - Index pronostiques
Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875-885.Facteurs de Risque - Index pronostiques
Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict outcomes in classic Hodgkin lymphoma:a correlative study from the E2496 Intergroup trial. Blood 2012;120(16):3280-7. Facteurs de Risque - Index pronostiques
The International Non-Hodgkin Lymphoma Prognostic Factor Project. N Engl J Med 1993 ;329 :987.Facteurs de Risque - Index pronostiques
Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der Schueren E et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin´s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73: 47-56Facteurs de Risque - Index pronostiques
Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999.17:1244-53.Evaluation de la r‚ponse, TEP-FDG
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86. Evaluation de la r‚ponse, TEP-FDG
Cheson BD, Role of functional imaging in the management of lymphoma. J Clin Oncol, 2011, 29 :1844-1854. Evaluation de la r‚ponse, TEP-FDG
Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-81Evaluation de la r‚ponse, TEP-FDG
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752.Evaluation de la r‚ponse, TEP-FDG
Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica 2010;95:1046-8.Evaluation de la r‚ponse, TEP-FDG
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin’s lymphoma. Blood. 2006;107:52-59.Evaluation de la r‚ponse, TEP-FDG
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8 Evaluation de la r‚ponse, TEP-FDG
Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009 Aug; 50(8): 1257-60.Evaluation de la r‚ponse, TEP-FDG
Meignan M, Gallamini A , Itti E , Barrington S, Haioun C, Polliack A. Report on the third international workshop on Interim Positron Emission Tomography in lymphoma held in Menton, France, 26 – 27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. Leuk Lymphoma. 2012 Oct;53(10):1876-81.Evaluation de la r‚ponse, TEP-FDG
Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014 Jan;55(1):31-7.Evaluation de la r‚ponse, TEP-FDG
Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, Van´t Veer MB, Lybeert ML et al. European Organization for Research and Treatment of cancer Lymphoma group Involved-field radiotherapy for advanced Hodgkin´s lymphoma. N Engl J Med 2003; 348: 2396-2406 Lymphome de Hodgkin - Traitement
Arakelyan N et al. Early Versus Late Intensification for Patients With High-Risk Hodgkin Lymphoma - 3 Cycles of Intensive Chemotherapy Plus Low-Dose Lymph Node Radiation Therapy Versus 4 Cycles of Combined Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Myeloablative Chemotherapy With Autologous Stem Cell Transplantation. Five-Year Results of a Randomized Trial on Behalf of the GOELAMS Group. Cancer 2008; 113 : 3323-30Lymphome de Hodgkin - Traitement
Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Annals of Oncology 21: 126–132, 2010Lymphome de Hodgkin - Traitement
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Lymphome de Hodgkin - Traitement
Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 2012;9(8):450-9.Lymphome de Hodgkin - Traitement
Carde P, Karrasch M, Fortpied C, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles, 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL):First results of the EORTC 20012 Intergroup randomized phase III clinical trial. J Clin Oncol 30, 2012 (suppl ;abstr 8002).Lymphome de Hodgkin - Traitement
Engert A, Borchmann P, Pluetschow A, et al: Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood 116:336, 2010 (abstr 765)Lymphome de Hodgkin - Traitement
Diehl V, Franklin J, Pfreundschuh M, et al. German Hodgkin Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin´s disease. N Engl J Med 2003;348:238-295.Lymphome de Hodgkin - Traitement
Eghbali H, Brice P, Creemers GY, et al. Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial. Proceedings of the Forty-seventh Annual Meeting of the American Society of Hematology, Blood 2005;106,11: 240a (Abstr. 814).Lymphome de Hodgkin - Traitement
Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28:4199-4206. Lymphome de Hodgkin - Traitement
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin´s Lymphoma: results of the HD8 trial of the German Hodgkin´s Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608 Lymphome de Hodgkin - Traitement
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vonblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495-3502.Lymphome de Hodgkin - Traitement
Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009; 27:4548-54 Lymphome de Hodgkin - Traitement
Engert A, Borchmann P, Pluetschow A, et al: Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood 2010;116:336,(abstr 765)Lymphome de Hodgkin - Traitement
Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010, 21 Suppl 5:v168-171. Lymphome de Hodgkin - Traitement
Engert A, Diehl V, Pluetschow A, et al: Reduced treatment intensity in Patients with early-stages Hodgkin’s lymphoma. N Engl J Med 2010; 363:640-652. Lymphome de Hodgkin - Traitement
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9.Lymphome de Hodgkin - Traitement
Engert A, Borchmann P, Pluetschow A, et al: Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood 116:336, 2010 (abstr 765)Lymphome de Hodgkin - Traitement
Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin´s lymphoma responding to front-line therapy. J Clin Oncol 2003 ; 21: 2320-2325 Lymphome de Hodgkin - Traitement
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009 Feb 10;27(5):805-11. Lymphome de Hodgkin - Traitement
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007; 357:1916-27Lymphome de Hodgkin - Traitement
Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79:270-77.Lymphome de Hodgkin - Traitement
Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol, 2005, 23 :9198-9207.Lymphome de Hodgkin - Traitement
Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013 Feb 20;31(6):684-91.Lymphome de Hodgkin - Traitement
Herbst C, Rehan FA, Brillant C, et al: Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010;95:494-500. Lymphome de Hodgkin - Traitement
Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol, 2009,27:5390-96.Lymphome de Hodgkin - Traitement
Jagadeesh D, Diefenbach C, Evens AM. Hodgkin lymphoma in older patients:challenges and opportunities to improve outcomes. Hematol Oncol, 2013, 31 Suppl 1:69-75. Lymphome de Hodgkin - Traitement
Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood, 2011;117:4208-4217.Lymphome de Hodgkin - Traitement
Meyer RM, Gospodarowicz MK, Connors JM, et al; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399-408. Lymphome de Hodgkin - Traitement
Meyer RM, Hoppe RT. Point/counterpoint :early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 2012;120(23):4488-95.Lymphome de Hodgkin - Traitement
Noordijk EM, Carde P, Mandard AM, Mellink WA, Monconduit M, Eghbali H et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin´s disease. Ann Oncol 1994; 5 suppl2: S107-S112. Lymphome de Hodgkin - Traitement
Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wassermann TH et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin´s disease. J Clin Oncol 2001; 19: 4238-4244. Lymphome de Hodgkin - Traitement
Proctor SJ et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38 : 795-806. Lymphome de Hodgkin - Traitement
Specht L, Yahalom J, Illidge T, et al. Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys, 2013 Jun 18. pii:S0360-3016(13)00534-8.Lymphome de Hodgkin - Traitement
Strauss DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood, 2004;104 :3483-3489.Lymphome de Hodgkin - Traitement
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s Lymphoma When High-Dose Salvage Is Planned. N Engl J Med 2011;365:203-12.Lymphome de Hodgkin - Traitement
von Tresckow B, Plütschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907-913,Lymphome de Hodgkin - Traitement
Ketterer N, Coiffier B, Thieblemont C, et al. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol 2013 Apr;24(4):1031-7.Lymphomes non hodgkiniens - Traitement
Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999; 17(1): 222-9.Rechutes - progression
Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, et al. Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Refractory/Relapsed Hodgkin’s Lymphoma: A Monocenter Prospective Study. Am J Haematol 2007; 82:122-127.Rechutes - progression
Corazzelli G, Angrilli F, D’Arco A, et al. Efficacy and safety of bendamustine for the traetment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013;160(2):207-15.Rechutes - progression
Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin’s disease. Annals Oncol 2002;13:112-116.Rechutes - progression
Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011; 117(16): 4208-17.Rechutes - progression
Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999; 17(2): 534-45.Rechutes - progression
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852): 1051-4.Rechutes - progression
Minn AY, Riedel E, Halpern J, et al. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. Br J Haematol 2012;159(3):329-39. Rechutes - progression
Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008; 26:5980-7.Rechutes - progression
Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev, 2013;6:CD009411.Rechutes - progression
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323): 2065-71.Rechutes - progression
Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2012;97: 310-317.Rechutes - progression
Van Den Neste E, Casasnovas O, André M, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica, 2013, 98(8):1185-1195.Rechutes - progression
von Tresckow B, Plütschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012Rechutes - progression
Moskowitz AJ ; Novel agents in Hodgkin lymphoma. Curr Oncol Rep 2012;14(5);419-23. Nouveaux traitements
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol, 2012, 30 :2183-2189. Nouveaux traitements
Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation :results of a phase II study. J Clin Oncol 2012;30(18):2197-203.Nouveaux traitements
Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 2005;23(30):7555-64.Fertilit‚é
Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P. Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials. J Clin Oncol. 2013 Jan 10;31(2):231-9. Fertilit‚é
Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin. Cancer Res. 2006;12(21):6487-93. Fertilit‚é
Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009; 27:4548-54 Fertilit‚é
Falorio S, Biasoli I, Luminari S, et al. Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors:final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. Hematol Oncol 2013 Jun;31(2):332-8. Fertilit‚é
Haukvik UKH, Dieset I, Bjøro T, Holte H, Fosså SD. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann. Oncol. 2006;17(9):1428-33. Fertilit‚é
Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol. 1997;20:354-7.Fertilit‚é
Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111(1):71-76. Fertilit‚é
van der Kaaij MA, Heutte N, Le Stang N, Raemaekers JM, Simons AH, Carde P, et al. Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:2825-32.Fertilit‚é
van der Kaaij MA, Heutte N, van Echten-Arends J, Raemaekers JM, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Brice P, Bonmati C, Henry-Amar M, Kluin-Nelemans HC. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 2009 Dec;94(12):1691-7.Fertilit‚é
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;.20:3484-94 Complications non malignes - Seconds cancers
Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Ann Oncol 2011 Mar;22(3):681-8. Complications non malignes - Seconds cancers
Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma : meta-analysis of the randomised trials. Ann Oncol. 2006;17:1749-60. Complications non malignes - Seconds cancers
Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin’s Lymphoma. J Clin Oncol 2007;25:1489-1497.Complications non malignes - Seconds cancers